Could a common supplement help sleep apnea patients? small study investigates
NCT ID NCT06311045
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This small study tests whether the supplement N-acetylcysteine (NAC) can reduce oxidative stress and inflammation in people with obstructive sleep apnea who are already using standard PAP therapy. Researchers want to see if the effects differ between men and women. The study involves 14 participants taking NAC or a placebo for four weeks.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- N-acetylcysteine (NAC)
- What this could lead to
- If it works, this could point toward a sex-specific treatment to reduce oxidative stress and inflammation in people with sleep apnea.
- What could go wrong
- This is a very small, early study with only 14 participants, so results may not apply to everyone. It looks at lab markers, not symptoms or long-term outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
14 people
The number who actually took part.
- Started
-
May 2024
- Expected to finish
-
May 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
55 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Apnea-hypopnea index ≥15 events/hr on portable sleep monitoring * HbA1c \<6.5% Exclusion Criteria: * Body mass index (BMI) ≥40 kg/m2; * Diagnosis of diabetes mellitus, defined as the use of any diabetes medication (including glucagon like peptide \[GLP\]-1 agonists) currently or in the previous three months or HbA1c ≥6.5%; * Shift work (i.e., working hours that routinely cause sleep initiation after 1:00 a.m.); * Another major sleep disorder (i.e., circadian rhythm disorder, any history of narcolepsy, concurrently diagnosed or medication-treated restless legs syndrome, concurrently diagnosed or medication-treated chronic insomnia with the exception of antidepressant therapy); * Regular use (more than twice/week) of an opioid/narcotic, benzodiazepine, or prescription sleep medication other than antidepressants currently or within the last month; * The use of N-acetylcysteine in any form (oral, intravenous, inhaled) in the last seven days * The use of other over-the-counter antioxidant therapies including vitamin C or vitamin E in the preceding 10 days * History of reduced ejection fraction heart failure, or chronic cardiac arrhythmia requiring medication or treatment; * Unstable or uncontrolled medical or psychiatric comorbidity requiring hospitalization or change in medication during the previous three months; * Use of biologics or immune modulators in the last year; * Use of systemic steroids during the previous three months; * Current tobacco smoking; * Inability to sign informed consent; * Currently use of positive airway pressure therapy or another OSA treatment (e.g., hypoglossal nerve stimulator, oral device); * Recent history of alcoholism or drug abuse (within the last three months) * Neurological condition that requires ongoing pharmacological therapy (e.g., Parkinson's disease, Alzheimer's dementia, multiple sclerosis, other degenerative neurological disease). * Pregnancy
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Obstructive sleep apnea are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
NYU Langone Health
New York, New York, 10016, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can catching sleep apnea early save brain development in down syndrome?
- Could a blood protein reveal hidden heart risks in sleep apnea?
- Does concentrating change your breathing? study probes Brain-Breath link in opioid users
- Can software read sleep studies as well as a specialist?
- Monthly shot aims to quiet sleep apnea and shed pounds
- Can light therapy shrink tonsils and ease Kids' sleep apnea?